LINAGLIPTIN

作品数：20被引量：62H指数：4
导出分析报告
相关领域：医药卫生更多>>
相关作者：李振中杨文沛黄祖良钱力陈华妮更多>>
相关机构：右江民族医学院百色学院中国医科大学更多>>
相关期刊：《药学进展》《Acta Pharmacologica Sinica》《World Journal of Gastroenterology》《World Journal of Diabetes》更多>>
相关基金：国家自然科学基金广西教育厅科研项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease被引量：10
《Neural Regeneration Research》2023年第8期1818-1826,共9页Hai-Yang Yu Tong Sun Zhen Wang Hong Li Duo Xu Jing An Lu-Lu Wen Jia-Yi Li Wen Li Juan Feng 
supported by the National Natural Science Foundation of China,Nos.81771271(to JF),31800898(to WL),81430025(to JYL),and U1801681(to JYL);Key Research and Development Program of Liaoning Province,No.2020JH2/10300047(to JF);the Key Field Research Development Program of Guangdong Province,No.2018B030337001(to JYL);the Outstanding Scientific Fund of Shengjing Hospital,No.M0475(to JF)。
Use of glucagon-like peptide-1 receptor agonist or dipeptidyl peptidase 4 inhibitor has been shown to lower the incidence of Parkinson's disease in patients with diabetes mellitus.Therefore,using these two treatments ...
关键词：diabetes mellitus dipeptidyl peptidase 4 inhibitor EXENDIN-4 glucagon-like peptide-1 receptor agonist 1-methyl-4-phenyl-1 2 3 6-TETRAHYDROPYRIDINE LINAGLIPTIN microglia NEUROINFLAMMATION NLRP3 inflammasome Parkinson's disease PYROPTOSIS 
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review被引量：2
《World Journal of Diabetes》2022年第12期1168-1183,共16页Viswanathan Mohan Subhash Wangnoo Sambit Das Rajnish Dhediya Kumar Gaurav 
BACKGROUND Cardiovascular outcome trials have demonstrated cardiovascular safety of glimepiride(a sulfonylureas) against dipeptidyl peptidase-4 inhibitor linagliptin.Gliclazide(another newer sulfonylureas) has shown s...
关键词：LINAGLIPTIN GLICLAZIDE HYPOGLYCEMIA Major cardiovascular adverse events Type 2 diabetes 
Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus被引量：3
《Journal of Chinese Pharmaceutical Sciences》2021年第8期692-698,共7页Rui Li Yanru Kong 
In the present study,we aimed to investigate the effects of linagliptin on inflammatory factors and carotid intima-media thickness(CIMT)in newly diagnosed type 2 diabetes mellitus(T2 DM)patients with carotid atheroscl...
关键词：LINAGLIPTIN Type 2 diabetes mellitus Carotid atherosclerosis disease Inflammatory factors Carotid intima-media thickness 
Cardioprotective effect of Linagliptin on diabetic Wistar rats被引量：1
《Journal of Chinese Pharmaceutical Sciences》2021年第4期334-346,共13页Rong Li Lihua Song Jie Liu Yang Bai Yuming Du Chunhua Lin Xiuyuan Su Zongxue Yu 
Diabetic cardiomyopathy(DCM)is an important cardiovascular complication of diabetes mellitus,while the pathogenesis of DCM has not been fully elucidated.In the present study,we aimed to investigate the effect of Linag...
关键词：Diabetic cardiomyopathy LINAGLIPTIN NRF2 Oxidative stress 
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects被引量：4
《Neuroscience Bulletin》2020年第4期407-418,共12页Gang Zhang Samuel Kim Xiaohuan Gu Shan Ping Yu Ling Wei 
supported by the John E. Steinhaus Endowment fund.
Dipeptidyl peptidase 4 (DPP-4) inhibitors have been shown to have neuroprotective effects in diabetic patients suffering from stroke, but less research has focused on patients with mild hyperglycemia below the thresho...
关键词：Cerebral ISCHEMIA HYPERGLYCEMIA DPP-4 inhibitor LINAGLIPTIN NEUROPROTECTION 
Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
《World Journal of Meta-Analysis》2019年第4期156-161,共6页Naina Mohamed Pakkir Maideen 
Dipeptidyl peptidase 4(DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Saxagliptin is a substrate of CYP3A4/5 enzymes while other DPP4 inhibitors such as sitagliptin, linaglip...
关键词：Drug interactions SITAGLIPTIN SAXAGLIPTIN LINAGLIPTIN Gemigliptin Teneligliptin VILDAGLIPTIN Anagliptin CYP3A4 P-GP EFFLUX pump 
Effect of Llinagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy
《Journal of Hainan Medical University》2019年第8期49-52,共4页Li-Yan Jia Xiao-Hui Cao Yan-Yun Hu Yu Bai Jun Wang 
Objective:To explore the effect of Linagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy.Methods: A total of 98 patients with diabetic nephropathy a...
关键词：Diabetic NEPHROPATHY LINAGLIPTIN METFORMIN Tumor NECROSIS factor receptor MONOCYTE CHEMOATTRACTANT protein-1 
Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
《World Journal of Diabetes》2018年第10期165-171,共7页Hidetaka Hamasaki Yasuteru Hamasaki 
AIM To evaluate the comparative effectiveness of anagliptin and linagliptin on the clinical parameters in patients with type 2 diabetes mellitus(T2 DM). METHODS A 2-year retrospective cohort study was conducted in pat...
关键词：Type 2 DIABETES MELLITUS Dipeptidyl peptidase-4 INHIBITOR Anagliptin LINAGLIPTIN CHOLESTEROL 
Linagliptin alleviates fatty liver disease in diabetic db/db mice被引量：3
《World Journal of Diabetes》2016年第19期534-546,共13页Svetlana V Michurina Irina Ju Ishenko Vadim V Klimontov Sergey A Archipov Natalia E Myakina Marina A Cherepanova Eugenii L Zavjalov Galina V Koncevaya Vladimir I Konenkov 
Supported by Grants from the Russian Ministry of Education and Science,Nos.14.621.21.0010,RFMEFI62114X0010 and14.619.21.0005,RFMEFI61914X0005
AIM To study the effects of linagliptin on the structural signs of non-alcoholic fatty liver disease(NAFLD) in db/db mice. METHODS Male diabetic db /db mice(BKS.Cg-Dock7m+/+Leprdb/J) aged 10 wk received the dipeptidyl...
关键词：Diabetes OBESITY Non-alcoholic FATTY liver disease Dipeptidyl PEPTIDASE 4 LINAGLIPTIN 
Effects of linagliptin and liraglutide on glucose- and angiotensin Ⅱ-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro被引量：3
《Acta Pharmacologica Sinica》2016年第10期1349-1358,共10页Xian-wei WANG Fen-xi ZHANG Fen YANG Zu-feng DING Nidhi AGARWAL Zhi-kun GUO Jawahar L MEHTA 
Acknowledgements This study was supported by grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development （Washington, DC, USA） （grant No BX-000282-05）, the National Natural Science Foundation of China （grant No 81370428 and 31401246） and Boehringer Ingelheim Pharmaceuticals, Inc （Ridgefield, CT, USA）.
Aim： Glucagon-like peptide-1 （GLP-1） agonists and dipeptidyl peptidase-4 （DPP-4） inhibitors can not only lower blood glucose levels, but also alleviate cardiac remodeling after myocardial ischemia and hypertensio...
关键词：cardiac remodeling cardiac fibroblast GLUCOSE angiotensin Ⅱ collagen formation cytoskeleton organization LINAGLIPTIN LIRAGLUTIDE 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部